Robinson-White Audrey J, Bossis Ioannis, Hsiao Hui-Pin, Nesterova Maria, Leitner Wolfgang W, Stratakis Constantine A
Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2009 Oct;94(10):4061-9. doi: 10.1210/jc.2009-0759. Epub 2009 Sep 22.
Carney complex, a multiple neoplasia syndrome, characterized primarily by spotty skin pigmentation and a variety of endocrine and other tumors, is caused by mutations in PRKAR1A, the gene that codes for the RIalpha subunit of protein kinase A (PKA). PKA controls cell proliferation in many cell types. The cAMP analogue 8-Cl-adenosine (8-Cl-ADO) is thought to inhibit cancer cell proliferation.
The objective of the study was to study the antiproliferative effects of 8-Cl-ADO on growth and proliferation in B-lymphocytes of Carney complex patients that have PKA defects and to determine whether 8-CL-ADO could be used as a therapeutic agent in the treatment of Carney complex-associated tumors.
We used a multiparametric approach (i.e. growth and proliferation assays, PKA, and PKA subunit assays, cAMP and (3)H-cAMP binding assays, and apoptosis assays) to understand the growth and proliferative effects of 8-Cl-ADO on human B-lymphocytes.
8-Cl-ADO inhibited proliferation, mainly through its intracellular transport and metabolism, which induced apoptosis. PKA activity, cAMP levels, and (3)H-cAMP binding were increased or decreased, respectively, by 8-Cl-ADO, whereas PKA subunit levels were differentially affected. 8-Cl-ADO also inhibited proliferation induced by G protein-coupled receptors for isoproterenol and adenosine, as well as proliferation induced by tyrosine kinase receptors.
8-Cl-ADO in addition to unambiguously inhibiting proliferation and inducing apoptosis in a PKA-independent manner also has PKA-dependent effects that are unmasked by a mutant PRKAR1A. Thus, 8-Cl-ADO could serve as a therapeutic agent in patients with Carney complex-related tumors.
卡尼综合征是一种多肿瘤综合征,主要特征为皮肤散在色素沉着以及多种内分泌肿瘤和其他肿瘤,它由PRKAR1A基因突变引起,该基因编码蛋白激酶A(PKA)的RIα亚基。PKA在多种细胞类型中控制细胞增殖。环磷酸腺苷(cAMP)类似物8-氯腺苷(8-Cl-ADO)被认为可抑制癌细胞增殖。
本研究旨在探讨8-Cl-ADO对患有PKA缺陷的卡尼综合征患者B淋巴细胞生长和增殖的抗增殖作用,并确定8-Cl-ADO是否可作为治疗卡尼综合征相关肿瘤的治疗药物。
我们采用多参数方法(即生长和增殖测定、PKA和PKA亚基测定、cAMP和³H-cAMP结合测定以及凋亡测定)来了解8-Cl-ADO对人B淋巴细胞的生长和增殖作用。
8-Cl-ADO主要通过其细胞内转运和代谢抑制增殖,进而诱导凋亡。8-Cl-ADO分别使PKA活性、cAMP水平和³H-cAMP结合增加或降低,而PKA亚基水平受到不同影响。8-Cl-ADO还抑制异丙肾上腺素和腺苷的G蛋白偶联受体诱导的增殖以及酪氨酸激酶受体诱导的增殖。
8-Cl-ADO除了能明确以不依赖PKA的方式抑制增殖并诱导凋亡外,还具有依赖PKA的作用,这些作用在突变的PRKAR1A存在时会显现出来。因此,8-Cl-ADO可作为卡尼综合征相关肿瘤患者的治疗药物。